Product
XmAb13676
1 clinical trial
2 indications
Indication
B-cell Non-Hodgkin's LymphomaIndication
Chronic Lymphocytic LeukemiaClinical trial
A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-Expressing Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-10-01